Survival Outcomes in Patients with Non-Endometrioid Uterine Malignancies at a Tertiary Cancer Centre in North Kerala, India: A Retrospective Analysis

Background and Objectives: Non-endometrioid uterine carcinomas and sarcomas are aggressive, rare malignancies, with the exception of typically indolent low-grade endometrial stromal sarcoma (LG-ESS). This 10.25-year study reports on the relative frequency, clinical presentation and survival outcomes of these tumours from a major tertiary centre in South India. Methods: Patients diagnosed with non-endometrioid uterine malignancies between 2011 and 2021 were retrospectively analysed. Clinical features, treatment regimens, recurrence patterns and follow-up data were collected to evaluate survival and prognostic variables. Primary objectives were to assess histological distribution, clinical presentation, overall survival (OS) and relapse-free survival (RFS) across non-endometrioid epithelial and non-epithelial subtypes. Secondary objectives were to evaluate subtype-specific recurrence patterns and survival prognostic factors. Results: Out of the 925 uterine malignancies evaluated, 255 were uncommon histologies (27.6%), comprising epithelial (n=185 (72.5%): serous carcinoma (SC) n=116, carcinosarcoma (CS) n=45, clear cell carcinoma (CCC) n=20, undifferentiated/squamous cell carcinoma n=4) and non-epithelial subtypes (n=70 (27.5%): leiomyosarcoma (LMS) n=35, LG-ESS n=22 and high-grade endometrial stromal sarcoma (HG-ESS) n=10, pleomorphic sarcoma n=3). The median patient age was 59 years, with 158 patients (62%) presenting at stage I and 230 patients (90.2%) undergoing curative-intent treatment. Statistically significant survival variations were observed across both groups (p<0.05). Among epithelial malignancies (median follow-up 56 months; 95% confidence interval (CI): 47.3-64.7), five-year OS and RFS differed significantly (p=0.003 and <0.001, respectively), with the highest five-year OS and RFS noted in SC (65.5% OS, 61.2% RFS) and CCC (65.8% OS,52.5% RFS), compared to markedly inferior outcomes in CS (37.1% OS, 23.6% RFS). Stage-stratified outcomes in SCs revealed a significant difference in five-year OS between early (stage I/II) versus advanced stages (stage III/IV) (70.2% vs 59.4%, p=0.042), though five-year RFS differences did not reach statistical significance (66.7% vs 53.8%, p=0.059). Similarly, non-epithelial subtypes (median follow-up 79 months; 95% CI: 54.2-103.8), demonstrated marked survival divergence (p<0.001 for OS and RFS); LG-ESS exhibited favourable outcomes (89.5% five-year OS, 80% five-year RFS), whereas HG-ESS (35.7% OS, 25% RFS) and LMS (30.8% OS, 16.3% RFS) demonstrated aggressive behaviour. Recurrence rates peaked in LMS (71.4%). Multivariable analysis identified curative-intent treatment as an independent predictor of improved OS (hazard ratio (HR): 0.33, 95% CI: 0.12-0.94, p=0.038). Time-dependent Cox regression revealed that disease recurrence markedly increased mortality hazard overall (HR: 18.9, 95% CI: 11.7-30.7, p<0.001), as well as within epithelial (HR: 16.4, p<0.001) and non-epithelial subgroups (HR: 33.7, p<0.001), with no significant interaction by histological class (epithelial versus non-epithelial; p=0.199) Interpretation and Conclusions: The relative frequency of epithelial subtypes mirrored global literature, whereas low-grade ESS and LMS occurred more frequently. Uterine SCs showed favourable early-stage survival, while local recurrences in LMS warrant multicentre evaluation.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2026-11-17
DOI
https://doi.org/10.7759/cureus.119849
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Survival Outcomes in Patients with Non-Endometrioid Uterine Malignancies at a Tertiary Cancer Centre in North Kerala, India: A Retrospective Analysis

Karthickeyan Duraisamy, Sairu Philip, Mohandoss Murugesan, Kalpita Samrat Shringarpure et al.
Cureus
Endometrial and Cervical Cancer Treatments
article

Survival Outcomes in Patients with Non-Endometrioid Uterine Malignancies at a Tertiary Cancer Centre in North Kerala, India: A Retrospective Analysis

Karthickeyan Duraisamy, Sairu Philip, Mohandoss Murugesan, Kalpita Samrat Shringarpure, Arun P Narendran, Greeshma K.E., Akhil Suresh
article en

Abstract

Background and Objectives: Non-endometrioid uterine carcinomas and sarcomas are aggressive, rare malignancies, with the exception of typically indolent low-grade endometrial stromal sarcoma (LG-ESS). This 10.25-year study reports on the relative frequency, clinical presentation and survival outcomes of these tumours from a major tertiary centre in South India. Methods: Patients diagnosed with non-endometrioid uterine malignancies between 2011 and 2021 were retrospectively analysed. Clinical features, treatment regimens, recurrence patterns and follow-up data were collected to evaluate survival and prognostic variables. Primary objectives were to assess histological distribution, clinical presentation, overall survival (OS) and relapse-free survival (RFS) across non-endometrioid epithelial and non-epithelial subtypes. Secondary objectives were to evaluate subtype-specific recurrence patterns and survival prognostic factors. Results: Out of the 925 uterine malignancies evaluated, 255 were uncommon histologies (27.6%), comprising epithelial (n=185 (72.5%): serous carcinoma (SC) n=116, carcinosarcoma (CS) n=45, clear cell carcinoma (CCC) n=20, undifferentiated/squamous cell carcinoma n=4) and non-epithelial subtypes (n=70 (27.5%): leiomyosarcoma (LMS) n=35, LG-ESS n=22 and high-grade endometrial stromal sarcoma (HG-ESS) n=10, pleomorphic sarcoma n=3). The median patient age was 59 years, with 158 patients (62%) presenting at stage I and 230 patients (90.2%) undergoing curative-intent treatment. Statistically significant survival variations were observed across both groups (p<0.05). Among epithelial malignancies (median follow-up 56 months; 95% confidence interval (CI): 47.3-64.7), five-year OS and RFS differed significantly (p=0.003 and <0.001, respectively), with the highest five-year OS and RFS noted in SC (65.5% OS, 61.2% RFS) and CCC (65.8% OS,52.5% RFS), compared to markedly inferior outcomes in CS (37.1% OS, 23.6% RFS). Stage-stratified outcomes in SCs revealed a significant difference in five-year OS between early (stage I/II) versus advanced stages (stage III/IV) (70.2% vs 59.4%, p=0.042), though five-year RFS differences did not reach statistical significance (66.7% vs 53.8%, p=0.059). Similarly, non-epithelial subtypes (median follow-up 79 months; 95% CI: 54.2-103.8), demonstrated marked survival divergence (p<0.001 for OS and RFS); LG-ESS exhibited favourable outcomes (89.5% five-year OS, 80% five-year RFS), whereas HG-ESS (35.7% OS, 25% RFS) and LMS (30.8% OS, 16.3% RFS) demonstrated aggressive behaviour. Recurrence rates peaked in LMS (71.4%). Multivariable analysis identified curative-intent treatment as an independent predictor of improved OS (hazard ratio (HR): 0.33, 95% CI: 0.12-0.94, p=0.038). Time-dependent Cox regression revealed that disease recurrence markedly increased mortality hazard overall (HR: 18.9, 95% CI: 11.7-30.7, p<0.001), as well as within epithelial (HR: 16.4, p<0.001) and non-epithelial subgroups (HR: 33.7, p<0.001), with no significant interaction by histological class (epithelial versus non-epithelial; p=0.199) Interpretation and Conclusions: The relative frequency of epithelial subtypes mirrored global literature, whereas low-grade ESS and LMS occurred more frequently. Uterine SCs showed favourable early-stage survival, while local recurrences in LMS warrant multicentre evaluation.

Cureus
Malabar Cancer Centre (IN), Sir Sayajirao General Hospital Medical College (IN), Kannur Medical College (IN)
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon